Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.70 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.51 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.51 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.51 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417139 | 0.91 | MAPK14 (0.63) | MAPK14MAPK11DDR1DDR2TNF | |
| SCHEMBL1383938 | 0.91 | MAPK14 (0.58) | MAPK14MAPK11 | |
| SCHEMBL1417370 | 0.90 | MAPK14 (0.59) | MAPK14MAPK11HPGD | |
| SCHEMBL1417227 | 0.90 | MAPK14 (0.61) | MAPK14MAPK11DDR1DDR2TNF | |
| SCHEMBL1417307 | 0.89 | MAPK14 (0.61) | MAPK14MAPK11HPGD | |
| SCHEMBL1416977 | 0.88 | MAPK14 (0.56) | MAPK14MAPK11DDR2 | |
| SCHEMBL1384750 | 0.88 | MAPK14 (0.59) | MAPK14MAPK11DDR1DDR2TNF | |
| SCHEMBL1417255 | 0.88 | MAPK14 (0.56) | MAPK14MAPK11 | |
| SCHEMBL1386388 | 0.87 | MAPK14 (0.66) | MAPK14MAPK11KIT | |
| SCHEMBL1383736 | 0.87 | MAPK14 (0.66) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| EP-2298743-A1 | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (CH) | 2011-03-23 | — | — | EP | claimed |
| WO-2007096151-A2 | INHIBITORS OF P38-KINASE FOR TREATMENT OF PULMONARY HYPERTENSION | NOVARTIS AG (CH) | 2007-08-30 | — | — | WO | claimed |
| JP-2007521278-A | — | — | 2007-08-02 | — | — | JP | claimed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | claimed |
| US-8580838-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8410160-B2 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410160-B2 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| EP-2298743-A1 | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-7863314-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2011-01-04 | — | — | US | disclosed |
| US-7863314-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2011-01-04 | — | — | US | disclosed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885MAPK11 38/4885DDR1 3049/4885 |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885MAPK11 40/4885DDR1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.